An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

patients will still need to pay for the professional clinic visits required for supervised administration of the nasal spray. "While I think [listing Spravato on the PBS] is a useful step ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

A new nasal spray that uses a form of ketamine to treat difficult-to-treat depression will soon become more accessible to tens of thousands of Australians. Spravato, which contains esketamine ...